NCT05203497View on ClinicalTrials.gov

Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-ZHER2.

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 22, 2021

Primary Completion Date

March 1, 2023

Study Completion Date

March 1, 2023

Conditions
Breast Cancer Female
Interventions
DRUG

SPECT

One single injection of 99mTc-ZHER2:41071, followed by gamma camera imaging after 2, 4, 6 and 24 hours.

Trial Locations (1)

Unknown

TomskNRMC, Tomsk

All Listed Sponsors
lead

Tomsk National Research Medical Center of the Russian Academy of Sciences

OTHER

NCT05203497 - Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-ZHER2. | Biotech Hunter | Biotech Hunter